Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2025, Vol. 19 ›› Issue (08): 612-617. doi: 10.3877/cma.j.issn.1674-0785.2025.08.009

• Review • Previous Articles    

Research progress of 5-hydroxytryptamine and ferroptosis-mediated septic cardiomyopathy

Yi Zhou1, Ronghua Huang1, Zhengjiang Liu1,2,()   

  1. 1 Graduate School of Youjiang Medical University for Nationalities, Baise 533000, China
    2 Department of Cardiovascular Medicine, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, China
  • Received:2025-07-07 Online:2025-08-30 Published:2025-12-30
  • Contact: Zhengjiang Liu

Abstract:

Sepsis can lead to multiple systemic complications, with myocardial injury being one of the most frequent and severe complications, and serving as a crucial prognostic marker in septic patients. Ferroptosis, a recently identified form of programmed cell death, has been shown to participate in the pathogenesis of septic cardiomyopathy (SCM). As an inflammatory mediator, 5-hydroxytryptamine (5-HT) has been demonstrated to promote sepsis progression, yet its precise mechanism in mediating cardiac injury via ferroptosis remains incompletely understood. This review systematically summarizes the mechanistic role of 5-HT in SCM, aiming to provide novel therapeutic targets and clinical strategies.

Key words: Sepsis, Ferroptosis, Myocardial injury, 5-hydroxytryptamine, Inflammatory response

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd